查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1530735

到 2030 年照護現場診斷市場預測：按產品類型、平台、配方、樣品、應用、最終用戶和地區進行的全球分析

Point-of-Care Diagnostics Market Forecasts to 2030 - Global Analysis By Product Type, Platform, Prescription, Sample, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2024 年全球照護現場診斷市場規模將達到 334 億美元，預計到 2030 年將達到 535 億美元，預測期內複合年成長率為 8.2%。

照護端 (POC) 診斷是在患者照護端或附近進行的醫學測試。這種方法可以快速診斷和及時治療，改善患者預後並減少後續觀察需求。 POC診斷包括多種測試，包括血糖監測、懷孕檢測、感染疾病檢測和心臟標記。用於 POC 診斷的技術旨在方便用戶使用，通常需要對醫療保健提供者和患者進行最少的培訓。這些測試可快速提供結果，對於重症加護環境、遠距環境和慢性病管理至關重要。 POC 診斷的便利性和速度有助於快速做出明智的臨床決策並提高醫療服務的效率。

根據美國疾病管制與預防美國（CDC）2021年發布的資料，美國約有3,840萬名糖尿病患者。

慢性疾病和感染疾病增加

由於人口老化、不健康的生活方式和環境變化等因素，糖尿病、癌症和心臟病等慢性病在世界各地變得越來越普遍。 POC 測試有助於早期發現和管理這些疾病。 COVID-19、HIV 和結核病等感染疾病也是主要促進因素，POC 測試可以實現快速診斷和干涉，從而促進市場成長。

嚴格的監管要求

嚴格的監管要求通常包括嚴格的測試、文件和核准流程，這些流程既耗時又昂貴。因此，公司可能會面臨將新的 POC 診斷設備推向市場的延遲，從而阻礙創新並降低進步造福患者的速度。對於中小企業和新興企業來說，達到監管標準的高昂成本尤其困難，並且會限制競爭力並抑制市場多樣性。

轉向分散式醫療保健

去中心化醫療模式專注於超越傳統醫院的範圍，為病人提供更貼近的照護。因此，對快速、便攜且易於使用的診斷工具的需求激增。 POC 診斷可以在患者所在的地方即時檢測和決策，無論是在家中、在診所還是在遠端位置，這與分散式醫療保健的目標完全一致。這項轉變將增加診斷服務的可近性，特別是在服務不足和農村地區，並減少對大型實驗室基礎設施的需求。

準確性和可靠性問題

與傳統的臨床測試相比，POC 診斷工具可以產生不同的結果。這種差異削弱了醫療保健專業人員和患者對 POC 診斷工具的信任，使他們不願意傳播這些工具。不準確或不一致的結果可能導致誤診、不適當的治療計劃，並最終導致患者預後不良，這是醫療機構的一個主要問題。此外，醫療保健提供者可能需要集中實驗室進行額外的驗證性測試來確認 POC 結果，這否定了快速診斷的主要好處。

COVID-19 的影響：

COVID-19 大流行對即時照護 (POC) 診斷市場產生了重大影響。對快速、準確和易於訪問的測試解決方案的迫切需求導致對 POC 診斷工具的需求空前激增。政府和醫療保健系統已優先考慮進行 POC 測試，以快速檢測和監測病毒，從而加速這些技術的創新和採用。監管機構也加快了核准流程，加快了市場准入速度。然而，供應鏈中斷和對 COVID-19 診斷的集中努力暫時使其他疾病的 POC 測試的開發和可用性黯然失色。

血糖監測套件預計在預測期內將成為最大的細分市場

血糖監測套件對於糖尿病管理至關重要，體現了 POC 診斷的優勢，可實現即時患者監測和即時決策，預計在預測期內將成長最快。該套件的廣泛採用正在推動 POC 市場的技術進步和消費者接受度。此外，血糖監測套件的成功刺激了針對其他慢性病的類似 POC 診斷工具開發的創新和投資，從而擴大了市場並改善了整體醫療保健服務。

分子診斷領域預計在預測期內複合年成長率最高

分子診斷領域預計在預測期內複合年成長率最高。這是因為這些先進技術可以快速識別病原體的遺傳物質，從而實現感染疾病、遺傳性疾病和癌症的精確診斷。將分子診斷整合到 POC 中推動了創新，從而開發了可攜式、方便用戶使用的儀器，可以快速提供實驗室品質的結果。這項進步擴大了 POC 診斷的應用，並透過及時介入改善了患者的治療結果。

比最大的地區

由於慢性病盛行率高、人口老化以及對早期診斷和個人化醫療的重視，預計北美將在預測期內佔據最大的市場佔有率。該地區受益於先進的醫療基礎設施、高額醫療支出以及強大的研發活動。此外，在美國和加拿大，POC 診斷擴大被引入各種環境，包括醫院、診所和居家醫療。 COVID-19 大流行進一步加速了對快速、準確的 POC 檢測的需求，凸顯了其在管理突發公共衛生事件和推動該地區市場成長的重要性。

複合年成長率最高的地區：

預計亞太地區在預測期內將維持最高複合年成長率。這是因為 FDA 等監管機構透過確保 POC 診斷設備的安全性和有效性，在塑造市場方面發揮重要作用。此外，人工智慧和行動醫療技術整合等技術進步正在推動創新並擴展 POC 診斷的能力。

提供免費客製化

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球照護現場市場：依產品類型

  • 血糖值監測套件
  • 傳染病檢查套件
  • 血液檢測套組
  • 膽固醇檢測套組
  • 懷孕/不孕症檢測套組
  • 凝血監測套件
  • 尿液檢查套件
  • 藥物濫用檢測套組
  • 心臟標記
  • 甲狀腺刺激素測試
  • 血氣/電解質
  • 其他產品類型

第6章全球照護現場診斷市場：按平台

  • 量油尺
  • 橫向流動化驗
  • 微流體
  • 分子診斷
  • 免疫檢測
  • 其他平台

第7章 全球照護現場市場：按處方箋

  • 基於處方箋
  • 場外測試

第8章全球照護現場市場：按樣本

  • 血
  • 鼻咽拭子
  • 尿
  • 其他樣品

第9章全球照護現場市場：依應用分類

  • 感染疾病
  • 心臟病學
  • 糖尿病
  • 腫瘤學
  • 血液學
  • 懷孕和生殖
  • 膽固醇
  • 其他用途

第10章全球照護現場市場：依最終使用者分類

  • 醫院
  • 診所及門診治療中心
  • 居家照護設置
  • 診斷實驗室
  • 學術研究所
  • 藥局
  • 其他最終用戶

第11章全球照護現場市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第12章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第13章 公司概況

  • Abbott
  • AccuBioTech Co., Ltd
  • Anbio Biotechnology Co., Ltd.
  • Becton, Dickinson and Company
  • bioMerieux SA
  • Chembio Diagnostics
  • Danaher Corporation
  • EKF Diagnostics
  • F. Hoffman-La Roche Ltd.
  • Instrumentation Laboratory
  • Nova Biomedical
  • Orasure Technologies, Inc.
  • PTS Diagnostics
  • Qiagen
  • Sekisui Diagnostics
  • Siemens Healthineers AG
  • Thermo Fisher Scientific
  • Trinity Biotech
  • Werfen
Product Code: SMRC26847

According to Stratistics MRC, the Global Point-of-Care Diagnostics Market is accounted for $33.4 billion in 2024 and is expected to reach $53.5 billion by 2030 growing at a CAGR of 8.2% during the forecast period. Point-of-Care (POC) Diagnostics are medical testing conducted at or near the site of patient care. This approach allows for rapid diagnosis and immediate treatment, enhancing patient outcomes and reducing the need for follow-up visits. POC diagnostics encompass a range of tests, including blood glucose monitoring, pregnancy tests, infectious disease detection, and cardiac markers. The technology used in POC diagnostics is designed to be user-friendly, often requiring minimal training for healthcare providers or even patients. These tests provide quick results, which are crucial in critical care settings, remote locations, and in managing chronic diseases. The convenience and speed of POC diagnostics help in making informed clinical decisions promptly, thus improving the efficiency of healthcare delivery.

According to 2021 data published by the Centers for Disease Control and Prevention (CDC), there are approximately 38.4 million people with diabetes in the U.S.

Market Dynamics:

Driver:

Rising prevalence of chronic and infectious diseases

Chronic diseases like diabetes, cancer, and heart disease are becoming increasingly common around the world, due to factors like aging populations, unhealthy lifestyles, and environmental changes. POC tests can help with early detection and management of these conditions. Infectious diseases like COVID-19, HIV, and tuberculosis are also a major driver, as POC tests enable rapid diagnosis and intervention which boosts the growth of the market.

Restraint:

Strict regulatory requirements

Strict regulatory requirements often involve rigorous testing, documentation, and approval processes that can be time-consuming and costly. Consequently, companies may face delays in bringing new POC diagnostic devices to market, hindering innovation and reducing the speed at which advancements can benefit patients. The high costs associated with meeting regulatory standards can be particularly challenging for smaller companies and startups, potentially limiting their ability to compete and stifling diversity in the market.

Opportunity:

Shift towards decentralized healthcare

Decentralized healthcare model emphasizes providing medical care closer to the patient, outside traditional hospital settings. As a result, the demand for rapid, portable, and easy-to-use diagnostic tools has surged. POC diagnostics enable immediate testing and decision-making at the patient's location, be it a home, clinic, or remote area, aligning perfectly with the goals of decentralized healthcare. This shift enhances accessibility to diagnostic services, especially in underserved and rural areas, reducing the need for extensive lab infrastructure.

Threat:

Accuracy and reliability concerns

POC diagnostic tools sometimes exhibit variability in results compared to traditional laboratory tests. This discrepancy can undermine healthcare professionals' and patients' confidence in these tools, leading to reluctance in their widespread adoption. Inaccurate or inconsistent results can result in misdiagnoses, inappropriate treatment plans, and ultimately poorer patient outcomes, which are critical concerns in medical practice. Moreover, healthcare providers may require additional confirmatory tests from centralized laboratories to verify POC results, counteracting the primary advantage of rapid diagnosis.

Covid-19 Impact:

The Covid-19 pandemic had a profound impact on the Point-of-Care (POC) Diagnostics market. The urgent need for rapid, accurate, and accessible testing solutions led to an unprecedented surge in demand for POC diagnostic tools. Governments and healthcare systems globally prioritized POC tests for quick detection and monitoring of the virus, accelerating innovation and adoption of these technologies. Regulatory bodies also expedited approval processes, allowing for faster market entry. However, supply chain disruptions and the intense focus on Covid-19 diagnostics temporarily overshadowed the development and availability of POC tests for other conditions.

The glucose monitoring kits segment is expected to be the largest during the forecast period

The glucose monitoring kits is expected to be the largest during the forecast period as these kits, essential for diabetes management, exemplify the benefits of POC diagnostics, enabling real-time monitoring and immediate decision-making for patients. Their widespread adoption has driven technological advancements and consumer acceptance in the POC market. Moreover, the success of glucose monitoring kits has spurred innovation and investment in developing similar POC diagnostic tools for other chronic conditions, thereby expanding the market and improving overall healthcare delivery.

The molecular diagnostics segment is expected to have the highest CAGR during the forecast period

The molecular diagnostics segment is expected to have the highest CAGR during the forecast period because these advanced techniques allow for the rapid identification of genetic material from pathogens, leading to precise diagnostics for infectious diseases, genetic disorders, and cancer. The integration of molecular diagnostics into POC settings has driven innovation, resulting in portable, user-friendly devices capable of delivering lab-quality results quickly. This advancement has expanded the applications of POC diagnostics, improved patient outcomes through timely intervention.

Region with largest share:

North America is projected to hold the largest market share during the forecast period owing to high prevalence of chronic diseases, an aging population, and a strong emphasis on early diagnosis and personalized medicine. The region benefits from advanced healthcare infrastructure, significant healthcare expenditure, and robust research and development activities. Moreover in the United States and Canada, there is a strong adoption of POC diagnostics in various settings, including hospitals, clinics, and home care. The Covid-19 pandemic further accelerated the demand for rapid and accurate POC testing, highlighting its importance in managing public health emergencies drives the market growth in this region.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period because regulatory bodies like the FDA play a crucial role in shaping the market by ensuring the safety and efficacy of POC diagnostic devices. Additionally, technological advancements, such as the integration of artificial intelligence and mobile health technologies, are driving innovation and expanding the capabilities of POC diagnostics.

Key players in the market

Some of the key players in Point-of-Care Diagnostics market include Abbott, AccuBioTech Co., Ltd, Anbio Biotechnology Co., Ltd., Becton, Dickinson and Company, bioMerieux S.A., Chembio Diagnostics, Danaher Corporation, EKF Diagnostics, F. Hoffman-La Roche Ltd., Instrumentation Laboratory, Nova Biomedical, Orasure Technologies, Inc., PTS Diagnostics, Qiagen, Sekisui Diagnostics, Siemens Healthineers AG, Thermo Fisher Scientific, Trinity Biotech and Werfen

Key Developments:

In June 2024, Abbott and the National Association of Community Health Centers (NACHC) have joined together to increase access to healthy foods and improve health through the Innovation Incubator initiative.

In June 2024, BD (Becton, Dickinson and Company) and Edwards Lifesciences today announced a definitive agreement under which BD will acquire Edwards' Critical Care product group ("Critical Care"), for $4.2 billion in cash, unlocking new value creation opportunities and enhancing BD's portfolio of smart connected care solutions.

In March 2024, Abbott, Real Madrid and the Real Madrid Foundation announced the extension of their partnership through Real Madrid's 2026-27 seasons. Abbott will remain Global Health Sciences and Nutrition Partner of Real Madrid Football Club and Global Partner of the Real Madrid Foundation.

Product Types Covered:

  • Glucose Monitoring Kits
  • Infectious Disease Testing Kits
  • Hematology Testing Kits
  • Cholesterol Testing Kits
  • Pregnancy and Fertility Testing Kits
  • Coagulation Monitoring Kit
  • Urinalysis Testing Kits
  • Drug Abuse Testing Kits
  • Cardiac Markers
  • Thyroid Stimulating Hormone Testing
  • Blood Gas/Electrolytes
  • Other Product Types

Platforms Covered:

  • Dipsticks
  • Lateral Flow Assays
  • Microfluidics
  • Molecular Diagnostics
  • Immunoassays
  • Other Platforms

Prescriptions Covered:

  • Prescription Based
  • Over The Counter Testing

Samples Covered:

  • Blood
  • Nasal & Oropharyngeal Swabs
  • Urine
  • Other Samples

Applications Covered:

  • Infectious Diseases
  • Cardiology
  • Diabetes
  • Oncology
  • Hematology
  • Pregnancy & Fertility
  • Cholesterol
  • Other Applications

End Users Covered:

  • Hospitals
  • Clinics & Ambulatory Care Centers
  • Home Care Settings
  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Pharmacies
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Point-of-Care Diagnostics Market, By Product Type

  • 5.1 Introduction
  • 5.2 Glucose Monitoring Kits
  • 5.3 Infectious Disease Testing Kits
  • 5.4 Hematology Testing Kits
  • 5.5 Cholesterol Testing Kits
  • 5.6 Pregnancy and Fertility Testing Kits
  • 5.7 Coagulation Monitoring Kit
  • 5.8 Urinalysis Testing Kits
  • 5.9 Drug Abuse Testing Kits
  • 5.10 Cardiac Markers
  • 5.11 Thyroid Stimulating Hormone Testing
  • 5.12 Blood Gas/Electrolytes
  • 5.13 Other Product Types

6 Global Point-of-Care Diagnostics Market, By Platform

  • 6.1 Introduction
  • 6.2 Dipsticks
  • 6.3 Lateral Flow Assays
  • 6.4 Microfluidics
  • 6.5 Molecular Diagnostics
  • 6.6 Immunoassays
  • 6.7 Other Platforms

7 Global Point-of-Care Diagnostics Market, By Prescription

  • 7.1 Introduction
  • 7.2 Prescription Based
  • 7.3 Over The Counter Testing

8 Global Point-of-Care Diagnostics Market, By Sample

  • 8.1 Introduction
  • 8.2 Blood
  • 8.3 Nasal & Oropharyngeal Swabs
  • 8.4 Urine
  • 8.5 Other Samples

9 Global Point-of-Care Diagnostics Market, By Application

  • 9.1 Introduction
  • 9.2 Infectious Diseases
  • 9.3 Cardiology
  • 9.4 Diabetes
  • 9.5 Oncology
  • 9.6 Hematology
  • 9.7 Pregnancy & Fertility
  • 9.8 Cholesterol
  • 9.9 Other Applications

10 Global Point-of-Care Diagnostics Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Clinics & Ambulatory Care Centers
  • 10.4 Home Care Settings
  • 10.5 Diagnostic Laboratories
  • 10.6 Academic & Research Institutes
  • 10.7 Pharmacies
  • 10.8 Other End Users

11 Global Point-of-Care Diagnostics Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Abbott
  • 13.2 AccuBioTech Co., Ltd
  • 13.3 Anbio Biotechnology Co., Ltd.
  • 13.4 Becton, Dickinson and Company
  • 13.5 bioMerieux S.A.
  • 13.6 Chembio Diagnostics
  • 13.7 Danaher Corporation
  • 13.8 EKF Diagnostics
  • 13.9 F. Hoffman-La Roche Ltd.
  • 13.10 Instrumentation Laboratory
  • 13.11 Nova Biomedical
  • 13.12 Orasure Technologies, Inc.
  • 13.13 PTS Diagnostics
  • 13.14 Qiagen
  • 13.15 Sekisui Diagnostics
  • 13.16 Siemens Healthineers AG
  • 13.17 Thermo Fisher Scientific
  • 13.18 Trinity Biotech
  • 13.19 Werfen

List of Tables

  • Table 1 Global Point-of-Care Diagnostics Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Point-of-Care Diagnostics Market Outlook, By Product Type (2022-2030) ($MN)
  • Table 3 Global Point-of-Care Diagnostics Market Outlook, By Glucose Monitoring Kits (2022-2030) ($MN)
  • Table 4 Global Point-of-Care Diagnostics Market Outlook, By Infectious Disease Testing Kits (2022-2030) ($MN)
  • Table 5 Global Point-of-Care Diagnostics Market Outlook, By Hematology Testing Kits (2022-2030) ($MN)
  • Table 6 Global Point-of-Care Diagnostics Market Outlook, By Cholesterol Testing Kits (2022-2030) ($MN)
  • Table 7 Global Point-of-Care Diagnostics Market Outlook, By Pregnancy and Fertility Testing Kits (2022-2030) ($MN)
  • Table 8 Global Point-of-Care Diagnostics Market Outlook, By Coagulation Monitoring Kit (2022-2030) ($MN)
  • Table 9 Global Point-of-Care Diagnostics Market Outlook, By Urinalysis Testing Kits (2022-2030) ($MN)
  • Table 10 Global Point-of-Care Diagnostics Market Outlook, By Drug Abuse Testing Kits (2022-2030) ($MN)
  • Table 11 Global Point-of-Care Diagnostics Market Outlook, By Cardiac Markers (2022-2030) ($MN)
  • Table 12 Global Point-of-Care Diagnostics Market Outlook, By Thyroid Stimulating Hormone Testing (2022-2030) ($MN)
  • Table 13 Global Point-of-Care Diagnostics Market Outlook, By Blood Gas/Electrolytes (2022-2030) ($MN)
  • Table 14 Global Point-of-Care Diagnostics Market Outlook, By Other Product Types (2022-2030) ($MN)
  • Table 15 Global Point-of-Care Diagnostics Market Outlook, By Platform (2022-2030) ($MN)
  • Table 16 Global Point-of-Care Diagnostics Market Outlook, By Dipsticks (2022-2030) ($MN)
  • Table 17 Global Point-of-Care Diagnostics Market Outlook, By Lateral Flow Assays (2022-2030) ($MN)
  • Table 18 Global Point-of-Care Diagnostics Market Outlook, By Microfluidics (2022-2030) ($MN)
  • Table 19 Global Point-of-Care Diagnostics Market Outlook, By Molecular Diagnostics (2022-2030) ($MN)
  • Table 20 Global Point-of-Care Diagnostics Market Outlook, By Immunoassays (2022-2030) ($MN)
  • Table 21 Global Point-of-Care Diagnostics Market Outlook, By Other Platforms (2022-2030) ($MN)
  • Table 22 Global Point-of-Care Diagnostics Market Outlook, By Prescription (2022-2030) ($MN)
  • Table 23 Global Point-of-Care Diagnostics Market Outlook, By Prescription Based (2022-2030) ($MN)
  • Table 24 Global Point-of-Care Diagnostics Market Outlook, By Over The Counter Testing (2022-2030) ($MN)
  • Table 25 Global Point-of-Care Diagnostics Market Outlook, By Sample (2022-2030) ($MN)
  • Table 26 Global Point-of-Care Diagnostics Market Outlook, By Blood (2022-2030) ($MN)
  • Table 27 Global Point-of-Care Diagnostics Market Outlook, By Nasal & Oropharyngeal Swabs (2022-2030) ($MN)
  • Table 28 Global Point-of-Care Diagnostics Market Outlook, By Urine (2022-2030) ($MN)
  • Table 29 Global Point-of-Care Diagnostics Market Outlook, By Other Samples (2022-2030) ($MN)
  • Table 30 Global Point-of-Care Diagnostics Market Outlook, By Application (2022-2030) ($MN)
  • Table 31 Global Point-of-Care Diagnostics Market Outlook, By Infectious Diseases (2022-2030) ($MN)
  • Table 32 Global Point-of-Care Diagnostics Market Outlook, By Cardiology (2022-2030) ($MN)
  • Table 33 Global Point-of-Care Diagnostics Market Outlook, By Diabetes (2022-2030) ($MN)
  • Table 34 Global Point-of-Care Diagnostics Market Outlook, By Oncology (2022-2030) ($MN)
  • Table 35 Global Point-of-Care Diagnostics Market Outlook, By Hematology (2022-2030) ($MN)
  • Table 36 Global Point-of-Care Diagnostics Market Outlook, By Pregnancy & Fertility (2022-2030) ($MN)
  • Table 37 Global Point-of-Care Diagnostics Market Outlook, By Cholesterol (2022-2030) ($MN)
  • Table 38 Global Point-of-Care Diagnostics Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 39 Global Point-of-Care Diagnostics Market Outlook, By End User (2022-2030) ($MN)
  • Table 40 Global Point-of-Care Diagnostics Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 41 Global Point-of-Care Diagnostics Market Outlook, By Clinics & Ambulatory Care Centers (2022-2030) ($MN)
  • Table 42 Global Point-of-Care Diagnostics Market Outlook, By Home Care Settings (2022-2030) ($MN)
  • Table 43 Global Point-of-Care Diagnostics Market Outlook, By Diagnostic Laboratories (2022-2030) ($MN)
  • Table 44 Global Point-of-Care Diagnostics Market Outlook, By Academic & Research Institutes (2022-2030) ($MN)
  • Table 45 Global Point-of-Care Diagnostics Market Outlook, By Pharmacies (2022-2030) ($MN)
  • Table 46 Global Point-of-Care Diagnostics Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.